Several studies reveal promising approaches to combat treatment-resistant cancers. Researchers developed antibody-bottlebrush conjugates that deliver high drug loads to tumors, potentially surpassing traditional antibody-drug conjugates in efficacy and safety. Another study identified lymph nodes as key orchestrators of immune responses essential for successful immunotherapy. Emerging fusion proteins combining immune checkpoint blockade with selective tumor microenvironment activation have shown preclinical activity. These innovations hold potential to improve outcomes in hard-to-treat cancers such as melanoma, neuroblastoma, and osteosarcoma.